Chronic Intestinal Pseudo-Obstruction: A Prokinetic Trial, or Evidence Too Thin to Chase
A single patient, twenty-nine and facing a lifetime disease with no drug that reliably works against it. The disagreement isn’t whether a prokinetic might help — it’s whether "might" is worth the trial when nobody has confirmed there’s any functioning muscle left for it to act on.
Sylvia M., a 29-year-old graduate student, is two years into a doctoral program in environmental science that recurrent hospitalizations have already pushed back by one full academic year. Her symptoms started at 24 with intermittent bloating and vomiting that progressed, over eighteen months, to recognized episodes of pseudo-obstruction — radiographically dilated small bowel loops with no mechanical cause on repeated cross-sectional imaging, confirming chronic intestinal pseudo-obstruction after a workup that ruled out scleroderma, mitochondrial disease, and a paraneoplastic process. She has had four hospitalizations in the past year, each requiring bowel rest and IV fluids for five to ten days, and has lost enough weight between episodes that her team has begun discussing supplemental parenteral nutrition as her baseline oral and enteral intake continues to fall short.
What the team doesn't yet know, and what genuinely divides the room, is what kind of CIPO she has. The disease can arise from a primarily myopathic process — the smooth muscle itself failing to contract effectively — or a primarily neuropathic one, where the enteric nervous system's signaling fails while the muscle retains more of its underlying contractile capacity, and that distinction matters directly for whether a prokinetic has anything to act on. The available options — low-dose erythromycin, a motilin-receptor agonist that stimulates migrating motor complex activity, or prucalopride, a 5-HT4 agonist more established in slow-transit constipation than in true pseudo-obstruction — both carry real but modest evidence, drawn mostly from small case series. The one randomized exception is small enough to be worth reading precisely: Emmanuel and colleagues ran a double-blind placebo-controlled crossover of prucalopride in CIPO as a multiple n-of-1 study, and four patients completed it. Prucalopride improved pain, bloating and nausea — but not bowel function — and three of those four completers had visceral myopathy, the pattern usually assumed least likely to respond. That is the whole controlled evidence base, and it points the opposite way from the mechanistic argument. Her own QTc is normal at baseline, which is the one thing that keeps low-dose erythromycin on the table at all given its QT-prolongation risk and its tachyphylaxis with continued use; prucalopride carries a cardiac monitoring burden of its own. Neither drug is likely to reverse her underlying disease process. The question is whether a real, if modest, chance at fewer hospitalizations is worth pursuing before her care shifts fully toward managing nutrition around a motility problem nobody expects to fix.
GI/nutrition joint clinic, treatment planning
I want to trial a prokinetic before we go further down the road toward parenteral nutrition. She’s 29, and even a modest reduction in hospitalization frequency would materially change her life and her ability to finish her degree. Her QTc is normal, so erythromycin isn't off the table on safety grounds, and I don’t think we need a large effect size to justify trying something with a real, if limited, mechanistic rationale before committing her further toward PN dependence.
I want to be honest about what the evidence actually is here: small case series, largely extrapolated from other motility disorders where prokinetics are better studied. The one controlled CIPO study we have — Emmanuel's crossover — had four completers, and what it showed was symptom improvement without any change in bowel function. That is not the outcome that keeps her out of the hospital. Her underlying pathology, whatever it turns out to be, isn’t something any available prokinetic reliably reverses. I’d rather optimize her nutritional support directly than pursue a drug trial that could add real side effects — erythromycin’s QT risk, prucalopride’s monitoring burden — without a correspondingly real benefit case behind it.
I’m not saying a prokinetic could never help anyone with CIPO — I’m saying we don’t actually know if there’s a plausible mechanism for it to help HER, and trying it without knowing that isn’t evidence-respecting caution, it’s just a different kind of guess.
I think you’re both reasoning past the one piece of information that would actually help decide this: whether her CIPO is primarily myopathic or neuropathic. That distinction has real bearing on whether a prokinetic has anything left to stimulate. A neuropathic pattern retains more of the underlying contractile apparatus a prokinetic could plausibly act on; a primarily myopathic pattern may have little functional muscle left regardless of which drug we choose. I'll concede the awkward part of my own position: three of Emmanuel's four responders were myopathic, which is the opposite of what that reasoning predicts. Four patients can't overturn the mechanism, but they're enough to stop me claiming the manometry will be decisive rather than just informative.
I’d get antroduodenal manometry and, if she’s already scheduled for any abdominal surgery for other reasons, a full-thickness biopsy, before committing to either position. If the pattern comes back neuropathic-predominant, I’d support the prokinetic trial the gastroenterologist is proposing. If it’s clearly myopathic-predominant, I think the nutrition-support-focused path is the more honest one, and we shouldn’t spend her tolerance for side effects chasing a mechanism that likely isn’t there.
Agreed: antroduodenal manometry scheduled before finalizing the prokinetic decision; nutritional optimization continues in the meantime regardless of the eventual answer.
Not agreed: what to do if manometry results are ambiguous or mixed rather than clearly myopathic or neuropathic. The gastroenterologist would still favor a cautious prokinetic trial in that scenario; the nutrition-support physician would not, absent a clearer mechanistic signal.